ImmunityBio, Inc. (IBRX)

NASDAQ: IBRX · IEX Real-Time Price · USD
6.67
0.43 (6.89%)
At close: Jan 14, 2022 4:00 PM
6.62
-0.05 (-0.75%)
After-hours:Jan 14, 2022 7:04 PM EST
Market Cap2.65B
Revenue (ttm)565,000
Net Income (ttm)-287.66M
Shares Out397.80M
EPS (ttm)-0.67
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,382,442
Open6.13
Previous Close6.24
Day's Range6.04 - 6.68
52-Week Range5.11 - 45.42
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateNov 18, 2021

About IBRX

ImmunityBio, Inc., a clinical-stage immunotherapy company, develops cell and immune therapies to treat cancers and infectious diseases. The company develops Anktiva (N-803), an IL-15 superagonist and PD-L1 that activates natural killer and T effector cells in combination with chemo and trodelvy to treat cancers, such as merkel cell carcinoma, advanced pancreatic cancer, and advanced triple negative breast cancer; and an albumin-linked formulation of doxorubicin (Aldoxorubicin) to treat breast cancer, hodgkin lymphoma, SCLC, sarcoma, and gliobla...

IndustryBiotechnology
Founded2014
CEOPatrick Soon-Shiong
Employees538
Stock ExchangeNASDAQ
Ticker SymbolIBRX
Full Company Profile

Financial Performance

Financial Statements

News

ImmunityBio Expands Manufacturing Capacity with State-of-the-Art Manufacturing Plant in New York for Global Pandemic ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company (“ImmunityBio”), today announced that it has entered into a definitive agreement to acquire...

3 days ago - Business Wire

ImmunityBio Awarded Seminal Patent on Natural Killer Cells

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, has been granted a U.S. patent (11,207,350 B2) for a novel natural killer (NK) cell therap...

1 week ago - Business Wire

Amyris, ImmunityBio Shares Trading Higher On COVID-19 Vaccine Joint Venture

Amyris Inc (NASDAQ: AMRS) and ImmunityBio (NASDAQ: IBRX) have completed their previously announced joint venture agreement to accelerate the commercialization of a next-generation COVID-19 vaccine. Upon...

Other symbols:AMRS
1 week ago - Benzinga

AMYRIS AND IMMUNITYBIO COMPLETE JOINT VENTURE FOR NEXT GENERATION COVID-19 RNA VACCINE

EMERYVILLE, Calif. and CULVER CITY, Calif.

Other symbols:AMRS
1 week ago - PRNewsWire

CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development in oncology and neurodegenerative dis...

3 weeks ago - Business Wire

ImmunityBio Announces Completion of $470 Million Post-merger Financing to Fund Late-stage Cancer Clinical Trials, Pha...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, has successfully raised an aggregate $470 million of equity and debt financing in 2021, wi...

3 weeks ago - Business Wire

ImmunityBio Expands Vaccine Program to Accelerate Use of “Mix-and-Match” Technologies in Developing and Manufacturing...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the expansion of the company's cancer and infectious disease vaccine progr...

1 month ago - Business Wire

Amyris, Inc. Reports Third Quarter 2021 Financial Results

EMERYVILLE, Calif., Nov. 8, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM oper...

Other symbols:AMRS
2 months ago - PRNewsWire

Amyris, ImmunityBio Join Forces For Next-Gen COVID-19 RNA Vaccine

Amyris Inc (NASDAQ: AMRS) has entered into a 50:50 joint venture arrangement with ImmunityBio Inc (NASDAQ: IBRX) to commercialize a next-gen COVID-19 vaccine. The parties have signed a binding term shee...

Other symbols:AMRS
2 months ago - Benzinga

Amyris Announces JV Partnership With ImmunityBio For Next Generation COVID-19 RNA Vaccine

EMERYVILLE, Calif., Nov. 8, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-MarketTM oper...

Other symbols:AMRS
2 months ago - PRNewsWire

ImmunityBio to Present at the Jefferies London Healthcare Conference

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that Founder, Executive Chairman and Global Chief Scientific and Medical O...

2 months ago - Business Wire

ImmunityBio Meets Endpoint In Second Indication Cohort In Bladder Cancer Trial

ImmunityBio Inc (NASDAQ: IBRX) has announced that Papillary disease (Cohort B) of its Phase 2/3 study of intravesical BCG plus Anktiva met its primary endpoints with disease-free survival of 57% at 12 m...

2 months ago - Benzinga

ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survi...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that Papillary disease (Cohort B), the second indication of its QUILT 3.03...

2 months ago - Business Wire

CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Tre...

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...

3 months ago - Business Wire

ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreati...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it has fully accrued the initial planned number of participants in Cohort ...

3 months ago - Business Wire

National Cancer Institute Selects ImmunityBio's N-803 IL-15 Receptor Agonist to Combine with Keytruda in 700-Site Lun...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the Lung Cancer Master Protocol (Lung-MAP) public-private partnership—whic...

3 months ago - Business Wire

ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced updated data from an ongoing bladder cancer trial showing sustained comple...

4 months ago - Business Wire

ImmunityBio Builds Commercial Team with the Appointment of Seasoned Marketing and Reimbursement Executives

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced two key executive appointments that bring industry-leading market growth a...

4 months ago - Business Wire

ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced Karim Chamie, M.D., Associate Professor of Urology, UCLA Department of Uro...

4 months ago - Business Wire

ImmunityBio Appoints Dr. Patrick Soon-Shiong to Global Chief Scientific and Medical Officer; Newly Created Role Will ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, appointed Patrick Soon-Shiong, M.D., to the newly created role of Global Chief Scientific ...

4 months ago - Business Wire

CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxor...

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerati...

5 months ago - Business Wire

ImmunityBio's Novel Immunotherapy NANT Cancer Vaccine Currently Being Studied in Multiple Clinical Trials Is Awarded ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a publicly traded immunotherapy company, announced today that it has been granted a patent by the U.S. Patent and Trademark Office for its propri...

5 months ago - Business Wire

ImmunityBio Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antige...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., (NASDAQ: IBRX), a publicly traded immunotherapy company, today announced authorization from the South Africa Health Products Regulatory Authority...

6 months ago - Business Wire

ImmunityBio and NantOmics Announce Clinical Validation of a Proprietary Method to Identify Unique Targets for Immunot...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a publicly traded immunotherapy company , and privately-held NantOmics today announced publication of a stepwise approach or “pipe...

6 months ago - Business Wire

FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 t-haNK to Increase Effectiveness of Trodelvy in Triple-Negative...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it has received FDA authorization to conduct a Phase 1b/2 open-label study...

7 months ago - Business Wire